Gliknik Raises $11.5M in Series C Financing
Gliknik Raises $11.5M in Series C Financing Gliknik Inc., a Baltimore, MD-based immunology company dedicated to patients with cancer and autoimmune disorders, completed an $11.5m Series C financing. The round was led by First In Ventures (FIV) with participation from SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings. Kyle Rusconi, a founder of FIV, is joining the Gliknik Board. Led by CEO David Block, Gliknik is an immunology company creating and advancing biologic drugs...
Source: finsmes.com